Asmanex now OK for younger children with asthma

Mometasone powder approved for younger children

The Schering-Plough Corp., is now approved for the maintenance treatment of asthma as a preventative therapy in patients ages four to 11 years old. Containing mometasone furoate inhalation powder, the new inhaler was previously approved as a

Related Videos
© 2023 MJH Life Sciences

All rights reserved.